Global Artificial Intelligence (AI) in Diabetes Management Market Size study & Forecast, by Type (Case-based Reasoning, Intelligent Data Analysis), by Application (Glucose Monitoring Devices, Diagnostic Devices, Insulin Delivery Devices, Other Devices) an

Global Artificial Intelligence (AI) in Diabetes Management Market Size study & Forecast, by Type (Case-based Reasoning, Intelligent Data Analysis), by Application (Glucose Monitoring Devices, Diagnostic Devices, Insulin Delivery Devices, Other Devices) and Regional Analysis, 2022-2029

Global Artificial Intelligence (AI) in Diabetes Management Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Artificial Intelligence (AI) in diabetes management refers to the use of advanced computing technologies, such as machine learning algorithms, to assist in the management and treatment of diabetes. The goal of AI in diabetes management is to help patients monitor and manage their blood sugar levels more effectively, reduce the risk of complications, and improve their overall quality of life. The major driving factors for the Global Artificial Intelligence (AI) in Diabetes Management Market are growing prevalence of diabetes, advancements in AI and machine learning and increasing demand for personalized healthcare. Moreover, growing adoption of wearable devices and rising advancements in AI and machine learning is creating lucrative growth opportunity for the market over the forecast period 2022-2029.

In Africa, the International Diabetes Federation (IDF) estimates that there were 19.4 million people with diabetes in 2019, and this number is expected to rise to 47 million by 2045. (Source: IDF Diabetes Atlas, 9th edition, 2019). Similarly, in South-East Asia, the IDF estimates that there were 88 million people with diabetes in 2019, and this number is expected to rise to 153 million by 2045. (Source: IDF Diabetes Atlas, 9th edition, 2019). Along with this, in the Western Pacific region, the IDF estimates that there were 159 million people with diabetes in 2019, and this number is expected to rise to 214 million by 2045. (Source: IDF Diabetes Atlas, 9th edition, 2019). However, the high cost of Artificial Intelligence (AI) in Diabetes Management stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Artificial Intelligence (AI) in Diabetes Management Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. The North American market is the largest market for AI in diabetes management, primarily driven by the high prevalence of diabetes in the region, the availability of advanced healthcare infrastructure, and the adoption of digital technologies. The US is the largest market in North America, followed by Canada. The Asia Pacific market for AI in diabetes management is expected to grow at a significant rate, driven by factors such as the high prevalence of diabetes, increasing healthcare expenditure, and growing adoption of digital technologies. China, India, and Japan are the major markets in the Asia Pacific region.

Major market player included in this report are:
Abbott Laboratories
Medtronic
Dexcom
Glooko
Diabeloop
Bigfoot Biomedical
Beta Bionics
One Drop
Diabnext
Tidepool

Recent Developments in the Market:
In May 2021, Abbott Laboratories announced that it had received FDA clearance for its AI-powered algorithm, which is designed to help people with diabetes better manage their glucose levels using the FreeStyle Libre 2 CGM system.
In February 2021, Medtronic announced that it had received CE Mark approval for its AI-powered predictive insulin dosing algorithm, which is designed to help people with diabetes avoid hypoglycemia.
In January 2021, Dexcom announced that it had acquired TypeZero Technologies, a company that develops AI-powered diabetes management solutions, to enhance its product offerings in the AI diabetes management space.
In December 2020, Glooko announced that it had received FDA clearance for its AI-powered insulin titration solution, which is designed to help healthcare providers adjust insulin doses for people with diabetes more efficiently.
Global Artificial Intelligence (AI) in Diabetes Management Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Application, Type, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:
By Type:
Case-based Reasoning
Intelligent Data Analysis
By Application:
Glucose Monitoring Devices
Diagnostic Devices
Insulin Delivery Devices
Other Devices

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Companies Mentioned

Abbott Laboratories
Medtronic
Dexcom
Glooko
Diabeloop
Bigfoot Biomedical
Beta Bionics
One Drop
Diabnext
Tidepool

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.